

Electronic Certificate

Version: 2 . 0

Document Number: US-CORP-2300006

Document Name: Corporate Overview Flashcard

Country: United States

Product: Corporate

Type: Material

Sub Type: Market Access

Classification:

Certification Statement

We certify that the final electronic form of this material is in accordance with the regulations set forth by the health authority for the country of this document, and is a fair and truthful presentation of the facts about the product.

Role	Signature
Craig Audet - Regulatory Approval (CRAU@ferring.com)	Meaning: As the Regulatory, I approve this document for use. Date: 11-Apr-2023 12:29:38 GMT+0000

**FERRING**

PHARMACEUTICALS

Helping People Live Better Lives

Reproductive Medicine & Maternal Health Gastroenterology | Orthopaedics | Uro-Oncology

At Ferring, we are committed to helping people build families and live better lives. In the United States, Ferring is a leader in reproductive medicine and maternal health, uro-oncology and in specialty areas within gastroenterology, including microbiome therapeutics and orthopaedics.

We know that people must always come first

- Globally, we reach millions of patients across 110 countries.
- We are 6,000+ strong across the globe, including more than 900 employees right here in the U.S.
- Globally, we bring over 70 years of experience developing innovative therapies across multiple conditions. We offer the most complete reproductive medicine portfolio in the U.S.
- We invest 15% of our global revenue in research and development. In the U.S., we aim to consistently grow revenue at a double-digit rate each year.

Committed to Innovation for Over 70 Years

Menopur®
(menotropins for injection)

Endometrin®
(progesterone) Vaginal Insert 100mg

Novarel®
(chorionic gonadotropin for injection, USP)

Fyremadel®
(ganirelix acetate) injection

Cervidil®
DINOPROSTONE 10mg
VAGINAL INSERT

REBYOTA™
(fecal microbiota, live-jslm) suspension,
for rectal use

CLENPIQ®
(sodium picosulfate, magnesium oxide,
and anhydrous citric acid) Oral Solution
10 mg/3.5 g/12 g per 160 mL bottle

cimzia®
(certolizumab pegol)

euflexxa®
1% SODIUM HYALURONATE

ADSTILADRIN®
(nadofaragene firadenovec-vncg)
suspension, for intravesical use / 3 x 10¹⁰ viral particles/mL

CIMZIA is a registered trademark of the UCB Group of Companies

US Pipeline

Therapy Area	Project / Potential Indication	Phase II	Phase III	Filed
Reproductive Medicine & Maternal Health	REKOVELLE Idiopathic male infertility	☑		
	REKOVELLE Infertility			☑
	FE 999906 Infertility		☑	
	FE 999903 Infertility		☑	
	FE 9992097 Postpartum hemorrhage		☑	
Orthopaedics	CONDOLIASE Radicular leg pain		☑	